Potential Future Goldmines? Opexa Therapeutics Inc (OPXA), Willbros Group Inc (WG) and Atossa Genetics Inc (ATOS)

Posted by admin May 15, 2015 0 Comment 1377 views

New York, NY – GDP INSIDER  –  05/15/2014.

This article discusses three companies: Opexa Therapeutics Inc (NASDAQ:OPXA), Willbros Group Inc (NYSE:WG) and Atossa Genetics Inc (NASDAQ:ATOS)

Opexa Therapeutics Inc (NASDAQ:OPXA) declined yesterday with the stock closing down 7.10% or $0.03 to close the day at $0.39 on slightly lower than average trading volume of 0.529 million, compared to its three month average trading volume of 0.533 million. The shares are down by 46% in past one month but are up over 0.5% in the past one week. The biopharmaceutical company, which focuses on the treatment of infectious and inflammatory diseases, has good fundamentals and a very strong quick ratio of 3.50 as well as one year price target estimate of $4, making it potentially a very good buy if bought at the right time.

Should You Invest In Opexa Therapeutics Inc Now? Read Our Free OPXA Analysis To Know More.

Willbros Group Inc (NYSE:WG) saw a decrease of 6.37% in value as the stock lost sixteen cents to move to a closing price of $2.35 on higher than average trading volume of 1.012 million, compared to its three month average trading volume of 0.985 million. The oil, gas and refinery engineering and construction service provider has been struggling so far this year, dealing with the difficult situation of unstable oil prices and is down 62.52% YTD. With RSI of 29.94 the stock is becoming undervalued which could make it attractive, but only when the sector as a whole has a period good news. Better to hold for now, or take a risk and invest in it for the long term.

What Does The Future Hold For Willbros Group Inc? Learn More About Company’s Trajectory In Our Free WG Analysis.

Atossa Genetics Inc (NASDAQ:ATOS) surged yesterday as the stock popped 15% to close the day at a closing price of $1.61 and saw its volume spiked to a figure of 2.505 million following the announcement of significant growth in its revenue for first quarter 2015. The company reported revenue of $1.9 million compared with $24,124 in the same quarter prior year and beat analysts’ estimate of $1.0 million of the quarter by $0.9 million. The development stage healthcare company is now enjoying quarterly revenue growth of 13.10% year on year and is trading well above its 200 day moving average of $1.47. The company is well funded and a healthy current ratio of 7.61 making it a stock to watch. With one year target price of $5, the stock is a good hold with a view to buy.

Find Out If Atossa Genetics Inc Can Stamp Its Mark On The Retail Market By Clicking Here For Free ATOS Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment